https://doi.org/10.4081/reumatismo.2022.1481
The prevalence and clinical spectrum of post-Covid syndrome in patients with rheumatic diseases: a single-center experience
Submitted: 26 January 2022
Accepted: 16 March 2022
Published: 3 May 2022
Accepted: 16 March 2022
Abstract Views: 2146
PDF: 611
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Post-coronavirus disease (COVID) syndrome (PCS) is a term used to describe the clinical condition of patients who have recovered from COVID-19 but are still experiencing prolonged effects of infection or persistent symptoms for longer than expected. Although PCS has been previously studied in the general population, it has not been investigated in a specific population of patients with inflammatory rheumatic disease (IRD). This study aims to evaluate the presence and frequency of PCS among our rheumatology outpatients. This is a cross-sectional study of patients with IRD whose symptoms persisted for 12 weeks after the detection of COVID-19 infection. The patients were assessed with a survey form during their routine clinic follow-up or by contacting them by phone. Patients’ demographics, diagnosis, medication, comorbidities, outcome of COVID-19, and symptoms related to PCS were collected. Fifty-three patients with IRD and COVID (mean age: 48.5 13.99 years, 71.7% women) were included. PCS was observed in 36 (67.9%) patients. Twenty-two (41.5%) of them had three or more symptoms; 14 (26.4%) had one or two symptoms. Although more than 30 symptoms were detected, the most frequent were fatigue and weakness. No significant relationship was detected between the development of PCS and gender, age, disease duration, presence of COVID-related complications, and the need for oxygen support, except for smoking which showed a protective effect (p=0.008). PCS was detected in more than half of the patients. There was no independent risk factor for the development of PCS, except smoking.
World Health Organization (WHO). Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva: World Health Organization (WHO); 16-24 February, 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-COVID-19-final-report.pdf Accessed: 06 December 2020.
Mahase E. COVID-19: What do we know about "long COVID"? BMJ. 2020; 370: m2815.
DOI: https://doi.org/10.1136/bmj.m2815
Greenhalgh T, Knight M, A'Court C, et al. Management of post-acute COVID-19 in primary care. BMJ. 2020; 370: m3026.
DOI: https://doi.org/10.1136/bmj.m3026
Goërtz YMJ, Van Herck M, Delbressine JM, et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020; 6: 00542-2020.
DOI: https://doi.org/10.1183/23120541.00542-2020
Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [Preprint]. 2021 Jan 30:2021.01.27.21250617.
DOI: https://doi.org/10.21203/rs.3.rs-266574/v1
Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021; 372: n136.
DOI: https://doi.org/10.1136/bmj.n136
Moreno-Pérez O, Merino E, Leon-Ramirez JM, et al; COVID19-ALC research group. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021; 82: 378-383.
DOI: https://doi.org/10.1016/j.jinf.2021.01.004
Carfì A, Bernabei R, Landi F; Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020; 324: 603-605.
DOI: https://doi.org/10.1001/jama.2020.12603
Garrigues E, Janvier P, Kherabi Y, et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020; 81: e4-e6.
DOI: https://doi.org/10.1016/j.jinf.2020.08.029
Sapkota HR, Nune A. Long COVID from rheumatology perspective - a narrative review. Clin Rheumatol. 2021; 30: 1-12.
Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network - United States, March-June 2020. Morbid Mortal Week Rep 2020; 69: 993.
DOI: https://doi.org/10.15585/mmwr.mm6930e1
Mahmoud MH, Alghamdi FA, Alghamdi GA, et al. Study of Post-COVID-19 Syndrome in Saudi Arabia. Cureus. 2021; 13: e17787.
DOI: https://doi.org/10.7759/cureus.17787
Liotti FM, Menchinelli G, Marchetti S, et al. Assessment of SARS-CoV-2 RNA test results among patients who recovered from COVID-19 with prior negative results. JAMA Intern Med. 2020; 181: 702-704.
DOI: https://doi.org/10.1001/jamainternmed.2020.7570
Vibholm LK, Nielsen SS, Pahus MH, et al. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMed. 2021; 64: 103230.
DOI: https://doi.org/10.1016/j.ebiom.2021.103230
McCallum M, Bassi J, De Marco A, et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv [Preprint]. 2021. Available online at: https://doi.org/10.1101/2021.03.31.437925 Accessed: 19 April 2021.
DOI: https://doi.org/10.1101/2021.03.31.437925
Motozono C, Toyoda M, Zahradnik J, et al. An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. bioRxiv [preprint]. 2021. Available online at: https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1 Accessed: 19 April 2021.
Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021; 27: 917-924.
DOI: https://doi.org/10.1038/s41591-021-01318-5
Proal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 2021; 12: 698169.
DOI: https://doi.org/10.3389/fmicb.2021.698169
How to Cite
Batıbay, S., Koçak Ulucaköy, R., Günendi, Z., & Göğüş, F. (2022). The prevalence and clinical spectrum of post-Covid syndrome in patients with rheumatic diseases: a single-center experience. Reumatismo, 74(1). https://doi.org/10.4081/reumatismo.2022.1481
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- T. Ziglioli, C. Bazzani, M. Filippini, S. Zingarelli, A. Giugno, R. Gorla, Early rheumatoid arthritis: a prospective study on how to induce the remission , Reumatismo: Vol. 60 No. 2 (2008)
- H. Olaosebikan, A. Azenabor, R. Akintayo, O. Adelowo, A. Ogbera, A. Brodie-Mends, Spectrum of musculoskeletal disorders in Nigerians with types 2 diabetes mellitus: prevalence and predictors , Reumatismo: Vol. 71 No. 4 (2019)
- A. Curti, C. Rampini, M. Gallazzi, F. Tramontana, G.P. Garbagna, Isolated muscular sarcoidosis mimicking a tumoral lesion , Reumatismo: Vol. 56 No. 1 (2004)
- P. Marson, G. Zanchin, C. Stefanutti, Some historical considerations on the inflammatory theory of atherosclerosis , Reumatismo: Vol. 56 No. 3 (2004)
- L. Cecchini, G. Coari, A. Iagnocco, G. Valesini, Brucellar spinal abscess. Case report , Reumatismo: Vol. 53 No. 3 (2001)
- H. Beyaztas, S. Aktas, E.M. Guler, E. Ata, Oxidative stress may be a contributing factor in fibromyalgia patients’ pain mechanisms , Reumatismo: Vol. 75 No. 3 (2023)
- P. Sarzi- Puttini, F. Atzeni, S. Stisi, M. Cazzola, Fibromialgia: chi deve rimodulare la percezione del dolore in questi pazienti? , Reumatismo: Vol. 60 No. s1 (2008)
- A. Gava, A. Furlan, F. Navaglia, M. Miorin, M. Razetti, D. Basso, M. Plebani, L. Punzi, Utility of denaturing high performance liquid chromatography (DHPLC) for the diagnosis of mevalonate kinase deficiency in periodic fevers of autoinflammatory nature suspicion , Reumatismo: Vol. 61 No. 3 (2009)
- P. Sfriso, F. Salaffi, S. Bombardieri, B. Canesi, C.M. Montecucco, S. Todesco, The risk/benefit profile of biologic drugs in real-world rheumatology practice. From ANTARES to MonitorNet , Reumatismo: Vol. 60 No. 2 (2008)
- F. De Leonardis, S. Aliverini, E. Bonacci, A.M. Buono, S. Bombardieri, G.F. Ferraccioli, C. Montecucco, L. Sinigaglia, F. Trotta, G. Valentini, Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the “3E initiative” , Reumatismo: Vol. 62 No. 1 (2010)
<< < 52 53 54 55 56 57 58 59 60 61 > >>
You may also start an advanced similarity search for this article.
